Tags

Type your tag names separated by a space and hit enter

Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease.
Pharmacol Rep. 2005 Nov-Dec; 57(6):701-12.PR

Abstract

Parkinson's disease (PD) is a chronic and progressive neurological disorder characterized by selective degeneration of dopaminergic neurons (DAergic) in the substantia nigra pars compacta (SNpc) and subsequent decrease in dopamine (DA) levels in the striatum. Although levodopa replacement therapy is initially effective in symptomatic treatment of parkinsonian patients, its effectiveness often declines and various levodopa-related side effects appear after long-term treatment. The disabling side effects of levodopa therapy include motor fluctuations such as the wearing-off or on-off phenomena, dyskinesias and psychiatric symptoms. Nowadays, DA receptor agonists are often regarded as first choice in de novo and young parkinsonian patients to delay the onset of levodopa therapy. In advanced stages of the disease, they are also used as adjunct therapy together with levodopa to retard the development of motor complications. DA receptor agonists mimic the endogenous neurotransmitter, dopamine, and act by direct stimulation of presynaptic (autoreceptors) and postsynaptic DA receptors. Next to their clinical role in treating parkinsonian patients, laboratory studies reported antioxidative and neuron-rescuing effects of DA receptor agonists either in vivo or in vitro. This may involve reduced DA turnover following autoreceptor stimulation and direct free radical scavenging activity. In this review, we focus on and summarize the recently reported effects of the most commonly used DA agonists either in clinical or in research studies relevant to PD treatment.

Authors+Show Affiliations

Radad K
Institute for Medical Chemistry, Veterinary Medical University, Veterinaerplatz 1, A-1210, Vienna, Austria.
Gille G
No affiliation info available
Rausch WD
No affiliation info available

MeSH

AnimalsAntioxidantsAntiparkinson AgentsBenzothiazolesBrainBromocriptineClinical Trials as TopicDopamineDopamine AgonistsDrug Evaluation, PreclinicalFree RadicalsHumansIndolesLevodopaNeuronsNeuroprotective AgentsParkinson DiseasePergolidePramipexoleReceptors, DopamineThiazoles

Pub Type(s)

Journal Article
Review

Language

eng

PubMed ID

16382188

Citation

Radad, Khaled, et al. "Short Review On Dopamine Agonists: Insight Into Clinical and Research Studies Relevant to Parkinson's Disease." Pharmacological Reports : PR, vol. 57, no. 6, 2005, pp. 701-12.
Radad K, Gille G, Rausch WD. Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacol Rep. 2005;57(6):701-12.
Radad, K., Gille, G., & Rausch, W. D. (2005). Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. Pharmacological Reports : PR, 57(6), 701-12.
Radad K, Gille G, Rausch WD. Short Review On Dopamine Agonists: Insight Into Clinical and Research Studies Relevant to Parkinson's Disease. Pharmacol Rep. 2005 Nov-Dec;57(6):701-12. PubMed PMID: 16382188.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Short review on dopamine agonists: insight into clinical and research studies relevant to Parkinson's disease. AU - Radad,Khaled, AU - Gille,Gabriele, AU - Rausch,Wolf-Dieter, PY - 2005/02/10/received PY - 2005/10/05/revised PY - 2005/12/31/pubmed PY - 2006/7/22/medline PY - 2005/12/31/entrez SP - 701 EP - 12 JF - Pharmacological reports : PR JO - Pharmacol Rep VL - 57 IS - 6 N2 - Parkinson's disease (PD) is a chronic and progressive neurological disorder characterized by selective degeneration of dopaminergic neurons (DAergic) in the substantia nigra pars compacta (SNpc) and subsequent decrease in dopamine (DA) levels in the striatum. Although levodopa replacement therapy is initially effective in symptomatic treatment of parkinsonian patients, its effectiveness often declines and various levodopa-related side effects appear after long-term treatment. The disabling side effects of levodopa therapy include motor fluctuations such as the wearing-off or on-off phenomena, dyskinesias and psychiatric symptoms. Nowadays, DA receptor agonists are often regarded as first choice in de novo and young parkinsonian patients to delay the onset of levodopa therapy. In advanced stages of the disease, they are also used as adjunct therapy together with levodopa to retard the development of motor complications. DA receptor agonists mimic the endogenous neurotransmitter, dopamine, and act by direct stimulation of presynaptic (autoreceptors) and postsynaptic DA receptors. Next to their clinical role in treating parkinsonian patients, laboratory studies reported antioxidative and neuron-rescuing effects of DA receptor agonists either in vivo or in vitro. This may involve reduced DA turnover following autoreceptor stimulation and direct free radical scavenging activity. In this review, we focus on and summarize the recently reported effects of the most commonly used DA agonists either in clinical or in research studies relevant to PD treatment. SN - 1734-1140 UR - https://www.unboundmedicine.com/medline/citation/16382188/Short_review_on_dopamine_agonists:_insight_into_clinical_and_research_studies_relevant_to_Parkinson's_disease_ DB - PRIME DP - Unbound Medicine ER -